DVN
AI Execution Plan
DVN down ~4% recently to $45 amid oil pullback and pre-earnings caution (May 5, 2026 expected profit dip). Analysts raised targets (avg $57, high $69). Dividend $0.24/share declared (payable Mar 31). Potential Devon-Coterra merger news. Mixed sentiment but surpassing 50/200-day SMAs.
Neutral overall: Moving averages balanced (6 buy/6 sell signals). MACD mixed (some buy at 0.97, others negative). RSI neutral. Recent breakout above 50/200-day SMAs bullish.
3-Month AI Outlook
Bullish. Analyst consensus 'Buy' with avg target $57 (+26% upside). Earnings catalyst May 5; potential merger with Coterra boosts growth. Energy sector rebound if oil stabilizes.
Option Chain
| Strike | Bid | Ask | IV % | Vol | OI | Time |
|---|---|---|---|---|---|---|
| $40.0 | 0.01 | 0.09 | 44.6% | 1 | 10 | 2026-04-15 10:23:40 |
| $41.0 | 0.07 | 0.12 | 42.6% | 34 | 129 | 2026-04-15 10:26:13 |
| $41.5 | 0.10 | 0.21 | 43.7% | 40 | 160 | 2026-04-15 10:26:13 |
| $42.0 | 0.15 | 0.26 | 42.6% | 366 | 489 | 2026-04-15 10:26:12 |
| $42.5 | 0.18 | 0.24 | 38.1% | 60 | 16 | 2026-04-15 10:26:14 |
| $43.0 | 0.26 | 0.33 | 37.7% | 307 | 86 | 2026-04-15 10:26:12 |
| $43.5 | 0.31 | 0.60 | 39.4% | 243 | 245 | 2026-04-15 10:26:12 |
| $44.0 | 0.57 | 0.61 | 38.5% | 21 | 10 | 2026-04-15 10:26:15 |
| $44.5 | 0.68 | 0.96 | 40.0% | 136 | 343 | 2026-04-15 10:26:12 |
| $45.0 | 0.96 | 0.99 | 37.5% | 1 | 31 | 2026-04-15 10:26:13 |
| $45.5 | 1.14 | 1.29 | 36.7% | 164 | 51 | 2026-04-15 10:26:13 |
| $46.0 | 1.48 | 1.60 | 37.7% | 139 | 22 | 2026-04-15 10:26:14 |
| $46.5 | 1.76 | 1.97 | 37.4% | 47 | 29 | 2026-04-15 10:25:44 |
| $47.0 | 1.57 | 2.35 | 24.1% | 29 | 8 | 2026-04-15 10:26:16 |
| $47.5 | 2.26 | 2.74 | 30.8% | 43 | 28 | 2026-04-15 10:26:13 |
| $48.0 | 2.91 | 3.33 | 41.9% | 59 | 48 | 2026-04-15 10:26:12 |
| $48.5 | 2.98 | 4.22 | 45.1% | 101 | 101 | 2026-04-15 10:25:07 |
| $49.0 | 3.43 | 4.66 | 45.9% | 27 | 40 | 2026-04-15 10:25:07 |
| $49.5 | 4.07 | 4.99 | 48.8% | 90 | 340 | 2026-04-15 10:26:11 |
| $50.0 | 4.42 | 5.46 | 45.2% | 100 | 103 | 2026-04-15 10:25:07 |
| $51.0 | 5.17 | 6.58 | 43.8% | 124 | 119 | 2026-04-15 10:26:11 |
| $52.0 | 6.16 | 7.80 | 62.1% | 125 | 173 | 2026-04-15 10:26:10 |
| $53.0 | 7.38 | 8.63 | 70.8% | 103 | 103 | 2026-04-15 10:26:03 |
| $54.0 | 8.41 | 9.58 | 76.0% | 101 | 103 | 2026-04-15 10:26:09 |
| $55.0 | 9.19 | 10.52 | 61.0% | 102 | 104 | 2026-04-15 10:26:15 |
| $56.0 | 10.13 | 11.77 | 82.4% | 111 | 110 | 2026-04-15 10:26:15 |
| $57.0 | 11.00 | 12.86 | 85.0% | 108 | 109 | 2026-04-15 10:25:51 |
| $58.0 | 11.58 | 14.08 | 65.1% | 108 | 109 | 2026-04-15 10:25:51 |
| $59.0 | 12.75 | 14.95 | 78.3% | 104 | 105 | 2026-04-15 10:25:51 |
| $61.0 | 14.59 | 17.10 | 85.2% | 108 | 110 | 2026-04-15 10:25:51 |
| Strike | Bid | Ask | IV % | Vol | OI | Time |
|---|---|---|---|---|---|---|
| $36.0 | 9.52 | 11.22 | 117.0% | 101 | 107 | 2026-04-14 10:08:02 |
| $37.0 | 8.47 | 10.42 | 112.5% | 90 | 103 | 2026-04-14 10:07:53 |
| $38.0 | 6.55 | 7.97 | 67.6% | 132 | 124 | 2026-04-15 10:25:52 |
| $39.0 | 5.50 | 6.86 | 43.0% | 106 | 115 | 2026-04-15 10:25:51 |
| $40.0 | 4.66 | 5.69 | 34.0% | 120 | 93 | 2026-04-15 10:25:09 |
| $41.0 | 3.67 | 4.76 | 36.8% | 99 | 95 | 2026-04-15 10:25:59 |
| $41.5 | 3.25 | 4.37 | 42.7% | 114 | 111 | 2026-04-15 10:26:10 |
| $42.0 | 2.77 | 3.83 | 37.4% | 121 | 100 | 2026-04-15 10:25:08 |
| $42.5 | 2.38 | 3.40 | 38.8% | 94 | 82 | 2026-04-15 10:25:07 |
| $43.0 | 2.11 | 3.02 | 42.6% | 31 | 30 | 2026-04-15 10:25:16 |
| $43.5 | 2.30 | 4.12 | 56.8% | 31 | 39 | 2026-04-14 10:06:03 |
| $44.0 | 1.66 | 1.87 | 38.7% | 33 | 34 | 2026-04-15 10:25:16 |
| $44.5 | 1.32 | 1.55 | 38.0% | 174 | 60 | 2026-04-15 10:26:01 |
| $45.0 | 1.09 | 1.21 | 37.7% | 205 | 92 | 2026-04-15 10:26:15 |
| $45.5 | 0.76 | 0.93 | 35.3% | 394 | 93 | 2026-04-15 10:26:15 |
| $46.0 | 0.55 | 0.73 | 35.1% | 221 | 61 | 2026-04-15 10:26:15 |
| $46.5 | 0.42 | 0.60 | 36.3% | 166 | 37 | 2026-04-15 10:26:13 |
| $47.0 | 0.32 | 0.47 | 37.1% | 356 | 46 | 2026-04-15 10:26:15 |
| $47.5 | 0.23 | 0.33 | 36.6% | 313 | 59 | 2026-04-15 10:26:13 |
| $48.0 | 0.15 | 0.25 | 36.6% | 55 | 35 | 2026-04-15 10:26:12 |
| $48.5 | 0.11 | 0.25 | 39.4% | 22 | 32 | 2026-04-15 10:25:32 |
| $49.0 | 0.06 | 0.18 | 38.7% | 48 | 70 | 2026-04-15 10:26:13 |
| $49.5 | 0.05 | 0.11 | 38.4% | 31 | 31 | 2026-04-15 10:25:32 |
| $50.0 | 0.09 | 0.11 | 43.7% | 21 | 33 | 2026-04-15 10:26:13 |
| $51.0 | 0.05 | 0.30 | 57.2% | 5 | 144 | 2026-04-15 10:26:04 |
| $52.0 | 0.05 | 0.23 | 60.5% | 200 | 578 | 2026-04-15 10:26:12 |
| $53.0 | 0.03 | 0.13 | 59.3% | 8 | 44 | 2026-04-15 10:25:16 |
Earnings History: DVN
Devon Energy Reports Strong Fourth-Quarter and Full-Year 2025 Results
Feb 17, 2026In the fourth quarter of 2025, Devon Energy Corp. reported solid financial results, with revenue not disclosed for this period. The company announced a net income of $X million and earnings per share (EPS) of $Y. During the same period, Devon's disciplined cash-return business model continued to generate free cash flow, allowing the company to maintain its commitment to returning capital to shareholders. The company also declared its quarterly fixed dividend as part of its strategic approach to provide value to investors. Looking ahead, Devon provided an outlook for 2026, emphasizing its focus on safe and sustainable operations across its diversified multi-basin portfolio, which includes a strong position in the Delaware Basin. Additionally, the company will host a conference call on February 18, 2026, at 10:00 a.m. Central time to discuss these results and answer questions from analysts and investors.
Devonian Health Group Reports Fourth Quarter and Annual Financial Results
Nov 26, 2025In the fourth quarter, Devonian Health Group generated distribution revenues of $1.3 million, resulting in a net loss of $0.4 million, equating to a loss of $0.003 per share. For the entire fiscal year ended July 31, 2025, the company reported distribution revenues of $23.6 million and a net loss of $6 million, or $0.041 per share. Research and development expenses for the fiscal year increased by 55.8% to $2 million, largely due to efforts related to the Thykamine™ pediatric atopic dermatitis phase 2/3 clinical study and preclinical studies for additional applications. Distribution revenues for the fourth quarter saw a significant decline of 87% year over year, attributed to the expiration of a distribution agreement for Dexlansoprazole. Devonian remains debt-free, with a cash position of $7 million as of July 31, 2025, down from $9.9 million at the beginning of the year. The company also appointed Pierre Labbé, CPA, to its Board of Directors, strengthening its leadership team as Jean Forcione resigned from the board. Additionally, Devonian continues to distribute two products through its subsidiary Altius, including Pantoprazole Magnesium and Cléo-35, which will be available until April 2026.
Strategy Overview
Jason Wheel is a systematic, AI‑enhanced trading framework built on probability theory and volatility‑based edge extraction. Designed for the US options market, the system focuses on constructing high‑probability Credit Spread strategies that capture Theta decay while maintaining strict quantitative risk controls to mitigate tail events and support long‑term, stable capital growth.
Rather than relying on directional speculation, the system operates as a closed‑loop asset engine integrating: Macro Risk Control, Multi-dimensional Quantitative Screening, AI-Assisted Decision Making, and Dynamic Position Management.
This architecture enables consistent, rules‑driven execution with an emphasis on risk‑adjusted returns.
Connect with Jason
- Substack: jasonwheel.substack.com
- Email: [email protected]